To include your compound in the COVID-19 Resource Center, submit it here.

CDP 870: Phase III

PFE will delay the start of the remaining Phase III trials of CDP 870 in RA.

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE